HCPCS Level II code J3403 designates Revakinagene taroretcel-lwey billed per implant, reflecting an implantable biologic or cellular therapy product. As advanced therapies expand, accurate coding for per-implant products matters for standardized billing, clinical registry tracking, and payer coverage determinations across the United States.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on what the code represents, typical sites of service, and common modifiers used with HCPCS Level II injectable and implantable product codes. The publication also summarizes expected benchmarking topics: allowable pricing and reimbursement considerations, claim adjudication patterns across major national payers, and coding nuances specific to per-implant biologic therapies.

The piece provides clinical context for implantable cellular or gene-related therapies and outlines the policy and billing items readers should monitor, including coverage criteria, prior authorization trends, and documentation expectations. Data not available in the input are noted where applicable.